Get all your news in one place.
100's of premium titles.
One app.
Start reading
AAP
AAP

Dayspring Pharma Announces Positive Topline Results from Phase II Clinical Trial of CG2001 for the Treatment of Androgenetic Alopecia (AGA)

SEOUL, South Korea, June 8, 2026 /PRNewswire/ -- Dayspring Pharma, a clinical-stage biotechnology company focused on innovative dermatology therapies, announced the first public disclosure of positive topline results from its Phase II randomized, double-blind, placebo-controlled trial of CG2001 at the 14th World Congress for Hair Research (WCHR) in Seoul, South Korea. The results were presented orally by Professor Cheng Zhou, Director of the Department of Dermatology at Peking University People's Hospital.

Professor Cheng Zhou presents the efficacy and safety results of CG2001, a topical combination of minoxidil and finasteride, at the 14th World Congress for Hair Research in Seoul, South Korea

CG2001 is a topical fixed-dose combination formulation containing minoxidil and finasteride, being evaluated for the treatment of male androgenetic alopecia.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.